Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 95.7% to $1.4 during Wednesday's

Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript

Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medi

Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's

Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T

—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disea

2025 was a critical year for Chemomab and nebokitug. Partnering discussions continue to advance alon

TEL AVIV, Israel, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemo

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ: CMMB - Get Free Report) saw a significant growth i

— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifyin

TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemo

—Nebokitug PSC Phase 3 Design Near Completion Following Positive FDA Feedback— —Regulatory Alignment

Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring c

PARR, CMMB and GES made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 23, 2025.

MQ, GES, TRV, CMMB and PARR have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 23, 2025.

TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemo

Juba, South Sudan, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Catholic Medical Mission Board (CMMB) is launch

— Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Execu

SPRING Trial Data Presented at BSG Live'25 Confirms the Clinical Potential of Nebokitug as a First-i

—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Pr

—New Patent s Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclero

— Reported Positive 48-Week Data from SPRING Trial — Nebokitug Treatment in PSC P atients with M ode

SPRING Trial Data Presented at Digestive Disease Week® 2025 Shows that Nebokitug at 15 and 48 Weeks 

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earning

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q

Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday afte

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares jumped 109% to $0.2115 after dipping around 48% o

  On Tuesday, 838 companies hit new 52-week lows.

  During Monday's trading, 528 companies set new 52-week lows.

  Monday saw 825 companies set new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.

  Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earn

    On Friday morning, 155 companies achieved new lows for the year.

Gainers BM Technologies, Inc. (NYSE: BMTX) shares climbed 26.4% to close at $11.82 on Tuesday aft

Gainers

Gainers

Gainers